These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 15084367)
1. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Lee L; Horowitz J; Frenneaux M Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367 [TBL] [Abstract][Full Text] [Related]
2. Metabolic modulation: a new therapeutic target in treatment of heart failure. Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344 [TBL] [Abstract][Full Text] [Related]
3. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Rupp H; Zarain-Herzberg A; Maisch B Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy in angina: a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agents. Jackson G Int J Clin Pract; 2001 May; 55(4):256-61. PubMed ID: 11406911 [TBL] [Abstract][Full Text] [Related]
5. Metabolic agents in the management of diabetic coronary patients: a new era. Marazzi G; Volterrani M; Rosano GM Int J Cardiol; 2008 Jun; 127(1):124-5. PubMed ID: 18199501 [TBL] [Abstract][Full Text] [Related]
6. Ranolazine for the management of coronary artery disease. Cheng JW Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457 [TBL] [Abstract][Full Text] [Related]
7. Role of metabolically active drugs in the management of ischemic heart disease. Schofield RS; Hill JA Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049 [TBL] [Abstract][Full Text] [Related]
8. Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Anderson JR; Nawarskas JJ Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056 [TBL] [Abstract][Full Text] [Related]
9. Chronic angina: new medical options for treatment. McCullough PA Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688 [TBL] [Abstract][Full Text] [Related]
10. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Melloni C; Newby LK Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903 [TBL] [Abstract][Full Text] [Related]
11. Metabolic therapeutics in angina pectoris: history revisited with perhexiline. Inglis S; Stewart S Eur J Cardiovasc Nurs; 2006 Jun; 5(2):175-84. PubMed ID: 16469541 [TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Rousseau MF; Pouleur H; Cocco G; Wolff AA Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536 [TBL] [Abstract][Full Text] [Related]
13. Modulation of myocardial metabolism: an emerging therapeutic principle. Horowitz JD; Chirkov YY; Kennedy JA; Sverdlov AL Curr Opin Cardiol; 2010 Jul; 25(4):329-34. PubMed ID: 20535068 [TBL] [Abstract][Full Text] [Related]
14. Modification of myocardial substrate use as a therapy for heart failure. Abozguia K; Clarke K; Lee L; Frenneaux M Nat Clin Pract Cardiovasc Med; 2006 Sep; 3(9):490-8. PubMed ID: 16932766 [TBL] [Abstract][Full Text] [Related]
18. Metabolic agents in the management of diabetic coronary patients: a new era. Celik T; Kursaklioglu H; Iyisoy A; Jata B Int J Cardiol; 2008 Jun; 127(1):133-4. PubMed ID: 17561287 [TBL] [Abstract][Full Text] [Related]
19. [The effect of antianginal preparations on the hemodynamics and metabolism of the ischemic myocardium]. Makolkin VI; Vakhliaev VD Eksp Klin Farmakol; 1996; 59(4):18-20. PubMed ID: 9026181 [TBL] [Abstract][Full Text] [Related]
20. Management of chronic stable angina pectoris. RodrÃguez-Ospina L; Montano-Soto L Bol Asoc Med P R; 2008; 100(4):39-47. PubMed ID: 19400528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]